A framework for genomic biomarker actionability and its use in clinical decision making
Vidwans, Smruti J. (CollabRx Inc. (USA))
Turski, Michelle L. (CollabRx Inc. (USA))
Janku, Filip (University of Texas. MD Anderson Cancer Center (USA))
Garrido-Laguna, Ignacio (University of Utah. Huntsman Cancer Institute (USA))
Munoz, Javier (Banner MD Anderson Cancer Center (USA))
Schwab, Richard (University of California. Moores Cancer Center (USA))
Subbiah, Vivek (University of Texas. MD Anderson Cancer Center (USA))
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia)
Kurzrock, Razelle (University of California. Moores Cancer Center (USA))
Universitat Autònoma de Barcelona

Data:	2014
Resum:	The increasing scope and availability of genetic testing options for patients suffering from cancer has raised questions about how to use results of molecular diagnostics to inform patient care. For some biomarkers (e. g. BRAF mutations in melanoma), standards exist that outline treatments for individuals harboring aberrations in the biomarker; however for the vast majority of genomic abnormalities, few guidelines exist. Clinical decision making and the therapeutic approach for a patient with a given cancer characterized by aberrations in different genes may be aided by the use of a biomarker actionability framework that provides levels of evidence regarding whether and how a molecular abnormality can be considered a therapeutically relevant biomarker. A gene may be considered theoretically actionable if it has a basis of actionability, such that clinically available drugs can target a gene product that drives the cancer or is differentially expressed in tumor versus normal elements. Herein, we discuss a possible framework for developing guidelines for actionability, as they relate to genomically-based cancer therapeutics.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Biomarker ; Clinical decision making ; Targeted therapies ; Predictive biomarkers
Publicat a:	Oncoscience, Vol. 1, Núm. 10 (October 2014) , p. 614-623, ISSN 2331-4737

DOI: 10.18632/oncoscience.90
PMID: 25593991

10 p, 687.1 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats